MLYS: Mineralys Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 465.83
Enterprise Value ($M) 368.56
Book Value ($M) 290.10
Book Value / Share 5.83
Price / Book 1.61
NCAV ($M) 236.41
NCAV / Share 4.75
Price / NCAV 1.97

Profitability (mra)
Return on Invested Capital (ROIC) -0.53
Return on Assets (ROA) -0.61
Return on Equity (ROE) -0.64

Liquidity (mrq)
Quick Ratio 8.55
Current Ratio 8.55

Balance Sheet (mrq) ($M)
Current Assets 267.73
Assets 268.25
Liabilities 31.32
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-13 13G/A Catalys Pacific Fund, LP 17.40 -5.73
11-13 13G/A HBM Healthcare Investments (Cayman) Ltd. 4.50 0.00
11-13 13G/A TCG Crossover GP II, LLC 5.00 -22.45
02-14 13G Adams Street Partners Llc 5.60
02-12 13D/A Samsara BioCapital, L.P. 10.30 12.61
02-12 13D/A Ra Capital Management, L.p. 9.99 55.59

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2024-08-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-14 56,314 261,784 21.51
2025-01-13 65,663 367,089 17.89
2025-01-10 58,184 388,794 14.97

(click for more detail)

Similar Companies
MGNX – MacroGenics, Inc. MGTX – MeiraGTx Holdings plc
MIST – Milestone Pharmaceuticals Inc. MNMD – Mind Medicine (MindMed) Inc.
MRNA – Moderna, Inc.


Financial data and stock pages provided by
Fintel.io